Effect of folic acid supplementation in pregnancy on preeclampsia: the folic acid clinical trial study

Shi Wu Wen, Josee Champagne, Ruth Rennicks White, Doug Coyle, William Fraser, Graeme Smith, Dean Fergusson, Mark C Walker, Shi Wu Wen, Josee Champagne, Ruth Rennicks White, Doug Coyle, William Fraser, Graeme Smith, Dean Fergusson, Mark C Walker

Abstract

Preeclampsia (PE) is hypertension with proteinuria that develops during pregnancy and affects at least 5% of pregnancies. The Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia: the Folic Acid Clinical Trial (FACT) aims to recruit 3,656 high risk women to evaluate a new prevention strategy for PE: supplementation of folic acid throughout pregnancy. Pregnant women with increased risk of developing PE presenting to a trial participating center between 8(0/7) and 16(6/7) weeks of gestation are randomized in a 1 : 1 ratio to folic acid 4.0 mg or placebo after written consent is obtained. Intent-to-treat population will be analyzed. The FACT study was funded by the Canadian Institutes of Health Research in 2009, and regulatory approval from Health Canada was obtained in 2010. A web-based randomization system and electronic data collection system provide the platform for participating centers to randomize their eligible participants and enter data in real time. To date we have twenty participating Canadian centers, of which eighteen are actively recruiting, and seven participating Australian centers, of which two are actively recruiting. Recruitment in Argentina, UK, Netherlands, Brazil, West Indies, and United States is expected to begin by the second or third quarter of 2013. This trial is registered with NCT01355159.

Figures

Figure 1
Figure 1
Schematic of different proposed mechanisms of action by which folic acid decreases the risk of developing preeclampsia.

References

    1. ACOG practice bulletion no. 33: diagnosis and management of preeclampsia and eclampsia. Obstetrics & Gynecology. 2002;99:159–167.
    1. Roberts JM, Lain KY. Recent insights into the pathogenesis of pre-eclampsia. Placenta. 2002;23(5):359–372.
    1. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. British Journal of Obstetrics and Gynaecology. 1992;99(7):547–553.
    1. Sibai BM. Hypertension in pregnancy. Obstetrics and Gynecology Clinics of North America. 1992;19(4):615–632.
    1. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertension in Pregnancy. 2003;22(2):203–212.
    1. Irgens HU, Reisæter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. British Medical Journal. 2001;323(7323):1213–1216.
    1. Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. British Medical Journal. 2003;326(7394):845–849.
    1. Meis PJ, Goldenberg RL, Mercer BM, et al. The preterm prediction study: risk factors for indicated preterm births. American Journal of Obstetrics and Gynecology. 1998;178(3):562–567.
    1. Ales KL, Frayer W, Hawks G, Auld PM, Druzin ML. Development and validation of a multivariate predictor of mortality in very low birth weight. Journal of Clinical Epidemiology. 1988;41(11):1095–1103.
    1. Whitfield MF, Grunau RVE, Holsti L. Extremely premature (≤800 g) schoolchildren: multiple areas of hidden disability. Archives of Disease in Childhood. 1997;77(2):F85–F90.
    1. Barker DJP. Fetal programming and public health. In: O’Brien PMS, Wheeler T, Barker DJP, editors. Fetal Programming: Influences on Development and Disease in Later Life. London, UK: RCOG Press; 1999. pp. 3–11.
    1. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. American Journal of Obstetrics and Gynecology. 1998;179(5):1359–1375.
    1. Wen SW, Chen X, Rodger M, et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. American Journal of Obstetrics and Gynecology. 2008;198(1):45.e1–45.e7.
    1. Wen SW, Zhou J, Yang Q, Fraser W, Olatunbosun O, Walker M. Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes. Canadian Medical Association Journal. 2008;179(12):1263–1268.
    1. Bodnar LM, Tang G, Ness RB, Harger G, Roberts JM. Periconceptional multivitamin use reduces the risk of preeclampsia. American Journal of Epidemiology. 2006;164(5):470–477.
    1. Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. American Journal of Epidemiology. 2002;156(9):806–812.
    1. Catov JM, Nohr EA, Bodnar LM, Knudson VK, Olsen SF, Olsen J. Association of periconceptional multivitamin use with reduced risk of preeclampsia among normal-weight women in the Danish National Birth Cohort. American Journal of Epidemiology. 2009;169(11):1304–1311.
    1. Li Z, Ye R, Zhang L, Li H, Liu J, Ren A. Folic acid supplementation during early pregnancy and the risk of gestational hypertension and preeclampsia. Hypertension. 2013;61(4):873–879.
    1. Timmermans S, Jaddoe VWV, Silva LM, et al. Folic acid is positively associated with uteroplacental vascular resistance: The Generation R Study. Nutrition, Metabolism and Cardiovascular Diseases. 2011;21(1):54–61.
    1. Herrmann W, Isber S, Obeid R, Herrmann M, Jouma M. Concentrations of homocysteine, related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status. Clinical Chemistry and Laboratory Medicine. 2005;43(10):1139–1146.
    1. Bánhidy F, Dakhlaoui A, Dudás I, Czeizel AE. Birth outcomes of newborns after folic Acid supplementation in pregnant women with early and late pre-eclampsia: a population-based study. Advances in Preventive Medicine. 2011;2011:7 pages.127369
    1. Charles DHM, Ness AR, Campbell D, Smith GD, Whitley E, Hall MH. Folic acid supplements in pregnancy and birth outcome: re-analysis of a large randomised controlled trial and update of Cochrane review. Paediatric and Perinatal Epidemiology. 2005;19(2):112–124.
    1. Merchant AT, Msamanga G, Villamor E, et al. Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension. Journal of Nutrition. 2005;135(7):1776–1781.
    1. Keating E, Gonçalves P, Campos I, Costa F, Martel F. Folic acid uptake by the human syncytiotrophoblast: interference by pharmacotherapy, drugs of abuse and pathological conditions. Reproductive Toxicology. 2009;28(4):511–520.
    1. Czeizel AE, Tomcsik M. Acute toxicity of folic acid in pregnant women. Teratology. 1999;60:3–4.
    1. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. The New England Journal of Medicine. 2006;354(15):1578–1588.
    1. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. Journal of the American Medical Association. 2007;297(21):2351–2359.
    1. Kim Y. Folic acid supplementation and cancer risk: point. Cancer Epidemiology Biomarkers and Prevention. 2008;17(9):2220–2225.
    1. Wien TN, Pike E, Wisløff T, Staff A, Smeland S, Klemp M. Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open. 2012;2(1)e000653
    1. Charles D, Ness AR, Campbell D, Smith GD, Hall MH. Taking folate in pregnancy and risk of maternal breast cancer. British Medical Journal. 2004;329(7479):1375–1376.
    1. Oakley GP, Mandel JS. Commentary: Folic acid fortification remains an urgent health priority. British Medical Journal. 2004;329(7479):p. 1376.
    1. Larsson SC, Giovannucci E, Wolk A. Folate and risk of breast cancer: a meta-analysis. Journal of the National Cancer Institute. 2007;99(1):64–76.
    1. Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. Journal of the American Medical Association. 2009;302(19):2119–2126.
    1. Armitage JM, Bowman L, Clarke RJ, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. Journal of the American Medical Association. 2010;303(24):2486–2494.
    1. Baggott JE, Oster RA, Tamura T. Meta-analysis of cancer risk in folic acid supplementation trials. Cancer Epidemiology. 2012;36(1):78–81.
    1. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Archives of Internal Medicine. 2010;170(18):1622–1631.
    1. Health Canada. Nutrition for a Healthy Pregnancy: Guideline for the Childbearing Years. Ottawa, Canada: Minister of Public Works and Government Services Canada; 1999.
    1. Wilson RD, Johnson J, Wyatt P, et al. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. Journal of Obstetrics and Gynaecology Canada. 2007;29(12):1003–1026.
    1. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. British Medical Journal. 2005;330(7491):565–567.
    1. Lemeshow S, Hosmer DW, Jr., Klar J, Lwanga JK. Adequacy of Sample Size in Health Studies. Geneva, Switzerland: World Health Organization; 1990.
    1. Laurence KM, Carter CO, David PA. Major central nervous system malformations in South Wales. II. Pregnancy factors, seasonal variation, and social class effects. British Journal of Preventive & Social Medicine. 1968;22(4):212–222.
    1. Record RG, McKeown T. Congenital malformations of the central nervous system. I. Survey of 930 cases. British Journal of Preventive and Social Medicine. 1949;3:183–219.
    1. Smithells RW, Sheppard S, Schorah CJ. Vitamin deficiencies and neural tube defects. Archives of Disease in Childhood. 1976;51(12):944–950.
    1. Hibbard E, Smithells RW. Folic acid metabolism and human embryopathy. The Lancet. 1965;285(7398):p. 1254.
    1. Thiersch JB. Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino P.G.A) administered by the oral route. American journal of obstetrics and gynecology. 1952;63(6):1298–1304.
    1. Wald N, Sneddon J, Densem J, Frost C, Stone R. Prevention of neural tube defects: results of the Medical Research Council vitamin study. The Lancet. 1991;338(8760):131–137.
    1. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. The New England Journal of Medicine. 1992;327(26):1832–1835.
    1. Fletcher J, Gurr A, Fellingham FR, Prankerd TAJ, Brant HA, Menzies DN. The value of folic acid supplements in pregnancy. Journal of Obstetrics and Gynaecology of the British Commonwealth. 1971;78(9):781–785.
    1. Fleming AF, Hendrickse JP, Allan NC. The prevention of megaloblastic anaemia in pregnancy in Nigeria. The Journal of obstetrics and gynaecology of the British Commonwealth. 1968;75(4):425–432.
    1. Laurence KM, James N, Miller MH. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. British Medical Journal. 1981;282(6275):1509–1511.
    1. Bernasconi AR, Liste A, Del Pino N, Rosa Diez GJ, Heguilén RM. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure. Nephrology. 2006;11(2):137–141.
    1. Chuang CZ, Boyles A, Legardeur B, Su J, Japa S, Lopez-S A. Effects of riboflavin and folic acid supplementation on plasma homocysteine levels in healthy subjects. The American journal of the medical sciences. 2006;331(2):65–71.
    1. Guven MA, Coskun A, Ertas IE, Aral M, Zencirci B, Oksuz H. Association of maternal serum CRP, IL-6, TNF-α, homocysteine, folic acid and vitamin b12 levels with the severity of preeclampsia and fetal birth weight. Hypertension in Pregnancy. 2009;28(2):190–200.
    1. Lindblad B, Zaman S, Malik A, et al. Folate, vitamin B12, and homocysteine levels in South Asian women with growth-retarded fetuses. Acta Obstetricia et Gynecologica Scandinavica. 2005;84(11):1055–1061.
    1. Powers RW, Evans RW, Majors AK, et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. American Journal of Obstetrics and Gynecology. 1998;179(6 I):1605–1611.
    1. Antoniades C, Shirodaria C, Warrick N, et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation. 2006;114(11):1193–1201.
    1. Brown KS, Huang Y, Lu Z, Jian W, Blair IA, Whitehead AS. Mild folate deficiency induces a proatherosclerotic phenotype in endothelial cells. Atherosclerosis. 2006;189(1):133–141.
    1. MacKenzie KE, Wiltshire EJ, Gent R, Hirte C, Piotto L, Couper JJ. Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus. Pediatrics. 2006;118(1):242–253.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera